PFG Investments LLC Acquires 324 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

PFG Investments LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,998 shares of the biotechnology company’s stock after buying an additional 324 shares during the period. PFG Investments LLC’s holdings in Sarepta Therapeutics were worth $3,283,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of SRPT. MassMutual Private Wealth & Trust FSB raised its position in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Sunbelt Securities Inc. raised its position in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank raised its position in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the last quarter. UMB Bank n.a. raised its position in shares of Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 197 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at approximately $59,000. 86.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on SRPT shares. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Raymond James reissued an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Evercore ISI reduced their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $178.71.

Insiders Place Their Bets

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $116.46 on Monday. Sarepta Therapeutics, Inc. has a 1 year low of $102.15 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company’s fifty day moving average price is $122.17 and its 200 day moving average price is $128.17. The stock has a market capitalization of $11.12 billion, a P/E ratio of 93.17 and a beta of 0.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.